The global carrier screening market is witnessing remarkable growth as healthcare systems increasingly emphasize early disease detection, reproductive planning, and preventive genetic testing. The market is projected to grow from USD 2.2 billion in 2023 to USD 5.4 billion by 2028, registering a strong CAGR of 19.7% during the forecast period.
Carrier screening helps identify individuals who carry genetic mutations associated with inherited disorders, enabling informed reproductive decisions and early intervention strategies. The growing awareness regarding genetic diseases, rising adoption of precision medicine, and increasing focus on preventive healthcare are among the key factors driving market expansion.
Healthcare providers and patients are increasingly recognizing the importance of carrier screening in reducing the risk of inherited genetic conditions such as cystic fibrosis, spinal muscular atrophy, sickle cell anemia, and thalassemia. Expanding applications of next-generation sequencing (NGS) technologies and advancements in molecular diagnostics are also accelerating market growth.
However, the shortage of skilled professionals capable of interpreting complex genetic data remains a major challenge for the industry.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72642285
Key companies operating in the global carrier screening market include Invitae Corporation (US), Fulgent Genetics (US), Eurofins Scientific (Germany), OPKO Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Quest Diagnostics Incorporated (US), Myriad Genetics, Inc. (US), Illumina, Inc. (US), Natera, Inc. (US), and DiaSorin S.p.A. (Italy).
Natera Expands Leadership in Genetic Screening
Natera, Inc. is one of the leading players in the carrier screening market, recognized globally for its expertise in cell-free DNA (cfDNA) testing across women’s health, oncology, and organ health applications.
The company develops and commercializes non-invasive genetic testing solutions designed to improve disease detection and reproductive health management. Natera operates through Product Revenue and Licensing & Other Revenues segments, with carrier screening services primarily delivered through its Product Revenue business.
Its product portfolio includes Horizon Advanced Carrier Screening, Panorama non-invasive prenatal testing, Vistra, Spectrum PGS, Spectrum PGD, Anora Products of Conception testing, and non-invasive paternity testing solutions.
Natera maintains a strong commercial presence through its direct sales force in the United States and a global network of approximately 100 laboratories and distribution partners. The company also continues to invest heavily in research and development, spending nearly USD 96 million on R&D activities in 2022 to strengthen its innovation capabilities and expand its market reach.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=72642285
Quest Diagnostics Strengthens Nationwide Genetic Testing Network
Quest Diagnostics Incorporated remains a major player in the carrier screening market through its extensive diagnostic information services and nationwide laboratory network.
The company operates through two business segments—Diagnostic Information Services (DIS) and Diagnostic Solutions. Through the DIS segment, Quest Diagnostics provides testing services across multiple clinical areas, including oncology, endocrinology, infectious diseases, immunology, cardiology, and reproductive genetics.
Quest offers comprehensive carrier screening panels designed to detect a wide range of inherited genetic disorders. Its large network of laboratories, patient service centers, and physician office laboratories across the United States allows the company to deliver accessible and scalable genetic testing solutions.
Fulgent Genetics Focuses on Flexible Genomic Testing Solutions
Fulgent Genetics is another important player driving innovation in the carrier screening and genetic testing landscape.
The company provides flexible and customizable genomic testing solutions for medical genetics, reproductive health, and cancer diagnostics. Fulgent Genetics offers an extensive catalog of genetic tests, including more than 18,000 single-gene tests, over 900 rare disease panels, whole genome sequencing, mitochondrial sequencing, and copy number variation analysis.
Fulgent operates seven laboratories across the United States and continues to strengthen its presence in the genetic testing market through high-quality sequencing services and advanced genomic technologies.
Future Outlook
The future of the carrier screening market looks highly promising as precision medicine and preventive healthcare become increasingly integrated into mainstream clinical practice. Growing awareness regarding inherited disorders, rising adoption of non-invasive genetic testing, and advancements in sequencing technologies are expected to drive sustained market growth.
Emerging trends such as AI-powered genomic interpretation, expanded carrier screening panels, and personalized reproductive healthcare are expected to reshape the market in the coming years. As healthcare systems continue focusing on early disease prevention and informed reproductive planning, demand for advanced carrier screening solutions is likely to rise significantly worldwide.
Enquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=72642285
